CONSOLIDATED STATEMENTS OF CASH FLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Mar. 31, 2012	Apr. 02, 2011	Apr. 03, 2010
Cash Flows from Operating Activities:
Net income	$ 66,886	$ 79,980	$ 58,370
Non cash items:
Depreciation and amortization	49,966	48,145	43,236
Stock compensation expense	9,286	10,810	10,267
Deferred tax expense	5,878	5,782	2,592
Loss/(gain) on sales of property, plant and equipment	772	674	(435)
Unrealized loss/(gain) from hedging activities	166	(614)	(1,368)
Contingent consideration income	(1,580)	(1,894)	(2,345)
(Reversal)/accretion of interest expense on contingent consideration	(574)	(416)	588
Asset impairment	0	0	15,686
Change in operating assets and liabilities:
(Increase)/decrease in accounts receivable, net	(10,539)	(3,920)	4,364
(Increase)/decrease in inventories	(32,528)	(2,560)	(1,665)
Decrease in prepaid income taxes	3,058	1,680	7,254
Decrease in other assets and other long-term liabilities	3,156	(470)	(13,809)
Tax benefit on exercise of stock options	1,958	4,941	2,670
Increase/(decrease) in accounts payable and accrued expenses	19,413	(18,683)	5,263
Net cash provided by operating activities	115,318	123,455	130,668
Cash Flows from Investing Activities:
Capital expenditures on property, plant and equipment	(53,198)	(46,669)	(56,304)
Proceeds from sale of property, plant and equipment	1,002	1,468	1,785
Acquisition of ACCS	0	(6,229)	0
Acquisition of Global Med Technologies	0	(128)	(58,052)
Acquisition of SEBRA	0	0	(12,845)
Acquisition of Neoteric	0	0	(6,613)
Acquisition of Medicell	0	0	(306)
Net cash used in investing activities	(52,196)	(51,558)	(132,335)
Cash Flows from Financing Activities:
Payments on long-term real estate mortgage	(815)	(632)	(754)
Net (decrease)/increase in short-term loans	(288)	(15,153)	6,184
Proceeds from employee stock purchase plan	3,723	3,681	2,909
Proceeds from exercise of stock options	15,475	40,896	17,270
Excess tax benefit on exercise of stock options	1,433	3,124	421
Share repurchase	(49,998)	(50,000)	(40,000)
Net cash used in financing activities	(30,470)	(18,084)	(13,970)
Effect of exchange rates on cash and cash equivalents	(498)	1,332	478
Net increase in Cash and Cash Equivalents	32,154	55,145	(15,159)
Cash and Cash Equivalents at Beginning of Year	196,707	141,562	156,721
Cash and Cash Equivalents at End of Period	228,861	196,707	141,562
Non-cash Investing and Financing Activities:
Transfers from inventory to fixed assets for placements of Haemonetics equipment	18,333	5,069	7,833
Debt assumed from acquisition	0	0	5,132
Supplemental Disclosures of Cash Flow Information:
Interest paid	414	487	563
Income taxes paid	$ 10,764	$ 16,669	$ 21,519